ATE196091T1 - Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung - Google Patents

Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung

Info

Publication number
ATE196091T1
ATE196091T1 AT97926647T AT97926647T ATE196091T1 AT E196091 T1 ATE196091 T1 AT E196091T1 AT 97926647 T AT97926647 T AT 97926647T AT 97926647 T AT97926647 T AT 97926647T AT E196091 T1 ATE196091 T1 AT E196091T1
Authority
AT
Austria
Prior art keywords
type
chemokine
binding proteins
poxviruses
cbp
Prior art date
Application number
AT97926647T
Other languages
English (en)
Inventor
D Grant Mcfadden
Alexandra Lucas
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Application granted granted Critical
Publication of ATE196091T1 publication Critical patent/ATE196091T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97926647T 1996-05-22 1997-05-21 Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung ATE196091T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1813796P 1996-05-22 1996-05-22
PCT/US1997/008590 WO1997044054A2 (en) 1996-05-22 1997-05-21 Type-2 chemokine binding proteins and methods of use therefor

Publications (1)

Publication Number Publication Date
ATE196091T1 true ATE196091T1 (de) 2000-09-15

Family

ID=21786445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926647T ATE196091T1 (de) 1996-05-22 1997-05-21 Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung

Country Status (20)

Country Link
EP (1) EP0901379B1 (de)
JP (1) JP2000511535A (de)
KR (1) KR20000015895A (de)
CN (1) CN1226171A (de)
AT (1) ATE196091T1 (de)
AU (1) AU3136197A (de)
BR (1) BR9710028A (de)
CA (1) CA2256568A1 (de)
CZ (1) CZ378998A3 (de)
DE (1) DE69703040T2 (de)
DK (1) DK0901379T3 (de)
ES (1) ES2152095T3 (de)
GR (1) GR3034805T3 (de)
IL (1) IL127166A0 (de)
NO (1) NO985412L (de)
NZ (1) NZ333456A (de)
PL (1) PL330149A1 (de)
PT (1) PT901379E (de)
TR (1) TR199802392T2 (de)
WO (1) WO1997044054A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB9916703D0 (en) 1999-07-16 1999-09-15 Alcami Antonio Viral protein binding compositions and methods
WO2001087324A1 (en) * 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
KR20030057529A (ko) 2000-09-08 2003-07-04 그리폰 테라퓨틱스, 인코포레이티드 합성 적혈구생성 자극 단백질
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP2004528010A (ja) 2000-10-11 2004-09-16 バイロン・セラピューティックス・インコーポレーテッド 免疫モジュレーションのための核酸およびポリペプチド
AU2002215727B8 (en) * 2000-12-04 2008-02-21 Viron Therapeutics Inc. Immunomodulatory protein derived from the yaba monkey tumor virus
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
DE10162869A1 (de) * 2001-12-20 2003-07-31 Alexander Cherkasky Invasive lineare halb-zyklische und zyklische Systeme zur Herauslockung der Krankheitserreger
GB0304531D0 (en) * 2003-02-27 2003-04-02 Isis Innovation Treatment
EP2266606B1 (de) * 2003-05-15 2014-09-10 Genentech, Inc. Verfahren und Zubereitungen zur Prävention und Behandlung von Blutvergiftung
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
EP2680010A1 (de) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2-screening-assays sowie entsprechende verfahren und zusammensetzungen
CN113234137B (zh) * 2021-06-21 2022-02-25 华中农业大学 分离自草鱼的CXCL20a蛋白在作为抗菌肽中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123515T3 (es) * 1991-03-29 1999-01-16 Immunex Corp Antagonistas de citoquinas a base de proteinas virales aisladas.
DE69628838T2 (de) * 1995-04-19 2004-05-06 The John P. Robarts Research Institute, London Chemokin bindendes protein und verfahren zu seiner verwendung
EP0862449A4 (de) * 1995-09-29 1998-11-11 Immunex Corp Chemokin-inhibitor

Also Published As

Publication number Publication date
EP0901379A2 (de) 1999-03-17
KR20000015895A (ko) 2000-03-15
NO985412D0 (no) 1998-11-20
WO1997044054A3 (en) 1998-05-14
DK0901379T3 (da) 2000-12-27
EP0901379B1 (de) 2000-09-06
NZ333456A (en) 2000-08-25
IL127166A0 (en) 1999-09-22
PT901379E (pt) 2001-02-28
DE69703040D1 (de) 2000-10-12
CN1226171A (zh) 1999-08-18
WO1997044054A2 (en) 1997-11-27
PL330149A1 (en) 1999-04-26
CZ378998A3 (cs) 1999-07-14
TR199802392T2 (xx) 1999-02-22
ES2152095T3 (es) 2001-01-16
JP2000511535A (ja) 2000-09-05
HK1017622A1 (en) 1999-11-26
AU3136197A (en) 1997-12-09
CA2256568A1 (en) 1997-11-27
GR3034805T3 (en) 2001-02-28
DE69703040T2 (de) 2001-05-03
BR9710028A (pt) 1999-08-10
NO985412L (no) 1999-01-20

Similar Documents

Publication Publication Date Title
ATE243526T1 (de) Chemokin bindendes protein und verfahren zu seiner verwendung
DE69703040D1 (de) Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung
ATE226633T1 (de) Bindungsdomänen in notch- und delta-proteinen
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
EP2267016A3 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
DE69433406D1 (de) Antikörper gegen cd40
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
WO1997044451A3 (en) Vasoactive amine binding molecules
ID21034A (id) Protein kinase dan penggunaannya
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
PT676413E (pt) Proteina de ligacao a interferoes alfa/beta, sua preparacao e utilizacao
EP0588036A3 (de) Zusammensetzung zur Isolierung von Apaminrezeptoren, Apaminbindungsprotein und deren Verwendungen.
DE69738945D1 (de) Rken
SE0003099D0 (sv) Adhesive protein and uses therefore
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee